University Center for Biomedical Research, National Council of Humanities Science and Technology (CONAHCYT)-University of Colima, Colima, Mexico.
Escuela Superior de Huejutla, Universidad Autónoma del Estado de Hidalgo, Hidalgo, México.
Neurosci Lett. 2023 Aug 24;812:137395. doi: 10.1016/j.neulet.2023.137395. Epub 2023 Jul 13.
Enteric glial cells are emerging as critical players in the regulation of intestinal motility, secretion, epithelial barrier function, and gut homeostasis in health and disease. Enteric glia react to intestinal inflammation by converting to a 'reactive glial phenotype' and enteric gliosis, contributing to neuroinflammation, enteric neuropathy, bowel motor dysfunction and dysmotility, diarrhea or constipation, 'leaky gut', and visceral pain. The focus of the minireview is on the impact of inflammation on enteric glia reactivity in response to diverse insults such as intestinal surgery, ischemia, infections (C. difficile infection, HIV-Tat-induced diarrhea, endotoxemia and paralytic ileus), GI diseases (inflammatory bowel diseases, diverticular disease, necrotizing enterocolitis, colorectal cancer) and functional GI disorders (postoperative ileus, chronic intestinal pseudo-obstruction, constipation, irritable bowel syndrome). Significant progress has been made in recent years on molecular pathogenic mechanisms of glial reactivity and enteric gliosis, resulting in enteric neuropathy, disruption of motility, diarrhea, visceral hypersensitivity and abdominal pain. There is a growing number of glial molecular targets with therapeutic implications that includes receptors for interleukin-1 (IL-1R), purines (P2X2R, A2BR), PPARα, lysophosphatidic acid (LPAR1), Toll-like receptor 4 (TLR4R), estrogen-β receptor (ERβ) adrenergic α- (α-R) and endothelin B (ETBR), connexin-43 / Colony-stimulating factor 1 signaling (Cx43/CSF1) and the S100β/RAGE signaling pathway. These exciting new developments are the subject of the minireview. Some of the findings in pre-clinical models may be translatable to humans, raising the possibility of designing future clinical trials to test therapeutic application(s). Overall, research on enteric glia has resulted in significant advances in our understanding of GI pathophysiology.
肠胶质细胞在调节肠道运动、分泌、上皮屏障功能和肠道稳态方面正成为关键角色,无论是在健康还是疾病状态下。肠胶质细胞通过转化为“反应性胶质表型”和肠胶质增生来对肠道炎症做出反应,导致神经炎症、肠神经病变、肠道运动功能障碍和运动障碍、腹泻或便秘、“肠漏”和内脏疼痛。本次迷你综述的重点是炎症对肠胶质细胞反应性的影响,这种反应性涉及到多种刺激,如肠道手术、缺血、感染(艰难梭菌感染、HIV-Tat 诱导的腹泻、内毒素血症和麻痹性肠梗阻)、胃肠道疾病(炎症性肠病、憩室病、坏死性小肠结肠炎、结直肠癌)和功能性胃肠道疾病(术后肠梗阻、慢性假性肠梗阻、便秘、肠易激综合征)。近年来,在胶质细胞反应性和肠胶质增生的分子发病机制方面取得了显著进展,导致肠神经病变、运动障碍、腹泻、内脏敏感性和腹痛。越来越多的与治疗相关的胶质分子靶点被发现,包括白细胞介素-1(IL-1R)、嘌呤(P2X2R、A2BR)、过氧化物酶体增殖物激活受体-α(PPARα)、溶血磷脂酸(LPAR1)、Toll 样受体 4(TLR4R)、雌激素-β 受体(ERβ)肾上腺素能α-(α-R)和内皮素 B(ETBR)、连接蛋白-43/集落刺激因子 1 信号(Cx43/CSF1)和 S100β/RAGE 信号通路。这些令人兴奋的新发展是本次迷你综述的主题。一些临床前模型中的发现可能具有转化为人类的潜力,这增加了设计未来临床试验以测试治疗应用的可能性。总的来说,对肠胶质细胞的研究使我们对胃肠道生理学有了重大的理解进展。